AC
PRVL

Athanor Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Athanor Capital’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-19,347
Closed -$288K – 721
2020
Q2 		$288K Buy
+19,347
New +$298K 0.01% 421

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Athanor Capital's PRVL Position: Q3 2020 in Review

Athanor Capital sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q3 2020, closing a stake of 19,347 shares — an estimated $288K sold.

Athanor Capital first reported a position in PRVL in Q2 2020 and held it in 1 quarter. The position peaked at $288K in Q2 2020. 76 funds tracked by Wall St. Rank hold PRVL as of Q3 2020.

  • Athanor Capital reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Athanor Capital sold 19,347 Prevail Therapeutics Inc. Common Stock shares in Q3 2020, an estimated $288K.
  • Athanor Capital first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Athanor Capital's Prevail Therapeutics Inc. Common Stock position peaked at $288K in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q3 2020.

Based on Athanor Capital's 13F filing for Q3 2020, filed 16 Nov 2020.